PRESS RELEASE

VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the
General Regulation of the French Financial Markets Authority (Autorité des Marchés
Financiers)


Paris, France, April 14, 2025
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com



Date Number of Shares Total number of voting rights
Outstanding
Total voting rights, Total voting rights,
theoretical1 exercisable2

March 31, 2025 47,426,851 49,193,374 49,171,256



***


About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to
revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for
humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand
possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the
Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge,
Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications
in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.




1
The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with
Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached,
including those for which voting rights have been suspended.
2
The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for
which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is
properly informed.
Contacts

Nanobiotix

Communications Department Investor Relations Department
Brandon Owens Craig West
VP, Communications SVP, Investor Relations
+1 (617) 852-4835 +1 (617) 583-0211
contact@nanobiotix.com investors@nanobiotix.com

Media Relations

France – HARDY Global – uncapped
Caroline Hardy Becky Lauer
+33 06 70 33 49 50 +1 (646) 286-0057
carolinehardy@outlook.fr uncappednanobiotix@uncappedcommunications.com